Flutamide
Flutamide is a non-steroidal inhibitor of the androgen receptor; it exhibits anticancer chemotherapeutic, anti-inflammatory, and anti-androgenic activities. Flutamide is clinically used to treat prostate cancer and polycystic ovary syndrome. In prostate cancer cells, flutamide induces S phase cell cycle arrest and inhibits cellular proliferation. Flutamide also decreases activation of NF-κB, release of pro-inflammatory cytokines, and activity of myeloperoxidase in animal models of hepatic trauma.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18925340
| Cas No. |
13311-84-7 |
|---|---|
| Purity |
≥98% |
| Formula |
C11H11F3N2O3 |
| Formula Wt. |
276.22 |
| Chemical Name |
2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- propanamide |
| IUPAC Name |
2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide |
| Synonym |
Drogenil; Euflex; Flucinom; Fugerel |
| Melting Point |
111.5-112.5°C |
| Solubility |
Insoluble in water. Soluble in DMSO. |
| Appearance |
A yellow crystalline powder |
Al-Saeedi F. Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study. Curr Ther Res Clin Exp. 2007 Jul;68(4):226-41. PMID: 24683213.
Shimizu T, Yu HP, Hsieh YC, et al. Flutamide attenuates pro-inflammatory cytokine production and hepatic injury following trauma-hemorrhage via estrogen receptor-related pathway. Ann Surg. 2007 Feb;245(2):297-304. PMID: 17245185.
